Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Long Tail Of Brands Pose Challenge For Indian Pharma Growth: PwC Report

This article was originally published in PharmAsia News

Executive Summary

The Indian drug industry may risk losing out if newer methods of drug marketing are not part of their long-term strategies.

You may also be interested in...



In India, GSK Takes A Deep Dive To Launch Revolade, Votrient At 75% Price Cut

MUMBAI - Industry analysts in India often credit GlaxoSmithKline Pharmaceuticals Ltd. for the tailor-made localized approach it takes to market products and price them in a way to suit patients who pay for medical costs largely out-of-pocket

Size Is Rewarded When Fostering Brand In India, But Pricing Has To Be Right: Elsevier Business Intelligence Webinar

MUMBAI - Becoming too big may have resulted in operational inefficiencies and deteriorating R&D output for global drug makers, but getting bigger may be a successful formula for branded generics businesses in emerging markets

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Topics

UsernamePublicRestriction

Register

SC080014

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel